Clinical Course of Treated Choroidal Neovascularization in Eyes with Pre-existing Geographic Atrophy: Case Series and Reappraisal of the Literature

References

• Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, Das A, Jonas JB, Keeffe J, Kempen JH, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1221ee1234. doi:10.1016/S2214-109X(17)30393-5.
   Web of Science ®Google Scholar
• Ferris FL 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, Sadda SR. Beckman initiative for macular research classification committee. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120:844e851. doi:10.1016/j.ophtha.2012.10.036.
   Web of Science ®Google Scholar
• Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115:116–26. doi:10.1016/j.ophtha.2007.03.008.
   PubMed Web of Science ®Google Scholar
• Blair CJ. Geographic atrophy of the retinal pigment epithelium: a manifestation of senile macular degeneration. Arch Ophthalmol. 1975;93:19–25. doi:10.1001/archopht.1975.01010020023003.
   PubMedGoogle Scholar
• Schatz H, McDonald HR. Atrophic macular degeneration. Rate of spread of geographic atrophy and visual loss. Ophthalmology. 1989;96:1541–51. doi:10.1016/s0161-6420(89)32694-7.
   PubMed Web of Science ®Google Scholar
• Holekamp N, Wykoff CC, Schmitz-Valckenberg S, Monés J, Souied EH, Lin H, Rabena MD, Cantrell RA, Henry EC, Tang F, et al. Natural history of geographic atrophy secondary to age-related macular degeneration: results from the prospective proxima A and B clinical trials. Ophthalmology. 2020;127(6):769–83. doi:10.1016/j.ophtha.2019.12.009.
   PubMed Web of Science ®Google Scholar
• Kaszubski P, Ben Ami T, Saade C, Smith RT. Geographic atrophy and choroidal neovascularization in the same eye: a review. Ophthalmic Res. 2016;55(4):185–93. doi:10.1159/000443209.
   PubMed Web of Science ®Google Scholar
• Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL 3rd, Fine SL, Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123:1751–61. doi:10.1016/j.ophtha.2016.03.045.
   PubMed Web of Science ®Google Scholar
• Bhisitkul RB, Mendes TS, Rofagha S, Enanoria W, Boyer DS, Sadda SR, Zhang K. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol. 2015;159:915–24. doi:10.1016/j.ajo.2015.01.032.
   PubMed Web of Science ®Google Scholar
• Abdelfattah NS, Al-Sheikh M, Pitetta S, Mousa A, Sadda SR, Wykoff CC. Treat-and-Extend Age-Related Macular Degeneration Study Group. Macular atrophy in neovascular age-related macular degeneration with monthly versus treat-and-extend ranibizumab: findings from the TREX-AMD Trial. Ophthalmology. 2017;124:215–23. doi:10.1016/j.ophtha.2016.10.002.
   PubMed Web of Science ®Google Scholar
• Sadda SR, Tuomi LL, Ding B, Fung AE, Hopkins JJ. Macular atrophy in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology. 2018;125:878e886. doi:10.1016/j.ophtha.2017.12.026.
   Web of Science ®Google Scholar
• Bailey C, Scott LJ, Rogers CA, Reeves BC, Hamill B, Peto T, Chakravarthy U, Harding SP. writing committee for the IVAN Study Group. Intralesional macular atrophy in anti-vascular endothelial growth factor therapy for age-related macular degeneration in the IVAN trial. Ophthalmology. 2019;126:75–86. doi:10.1016/j.ophtha.2018.07.013.
   PubMed Web of Science ®Google Scholar
• Querques G, Massamba N, Coscas F, Forte R, Souied EH. Choroidal neovascularisation complicating geographic atrophy in age-related macular degeneration. Br J Ophthalmol. 2012;96:1479–83. doi:10.1136/bjophthalmol-2012-302191.
   PubMed Web of Science ®Google Scholar
• Amaro MH, Roller AB. Intravitreal ranibizumab and bevacizumab therapy for choroidal neovascularization in age-related macular degeneration with extensive pre-existing geographic atrophy. Arq Bras Oftalmol. 2012;75:273–76. doi:10.1590/s0004-27492012000400011.
   PubMed Web of Science ®Google Scholar
• Holz FG, Sadda SR, Busbee B, Chew EY, Mitchell P, Tufail A, Brittain C, Ferrara D, Gray S, Honigberg L, et al. Chroma and spectri study investigators. efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials. JAMA Ophthalmol. 2018;136(6):666–77. doi:10.1001/jamaophthalmol.2018.1544.
   PubMed Web of Science ®Google Scholar
• Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, Blodi BA, Bottoni F, Chakravarthy U, Chew EY, et al. Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3. Ophthalmology. 2018;125(4):537–48. doi:10.1016/j.ophtha.2017.09.028.
   PubMed Web of Science ®Google Scholar
• Channa R, Sophie R, Bagheri S, Shah SM, Wang J, Adeyemo O, Sodhi A, Wenick A, Ying HS, Campochiaro PA. Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes. Am J Ophthalmol. 2015;159:9–19.e1-2. doi:10.1016/j.ajo.2014.09.012.
   PubMed Web of Science ®Google Scholar
• Munk MR, Ceklic L, Ebneter A, Huf W, Wolf S, Zinkernagel MS. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol. 2016;94:e757–e764. doi:10.1111/aos.13157.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Daniel E, Maguire MG, Grunwald JE, Martin ER, Martin DF, Ying GS. Comparison of age-related macular degeneration treatments trials research group. pseudodrusen and incidence of late age-related macular degeneration in fellow eyes in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123:1530–40. doi:10.1016/j.ophtha.2016.02.043.
   PubMed Web of Science ®Google Scholar
• Casalino G, Scialdone A, Bandello F, Chakravarthy U. Hyperreflective material as a biomarker in neovascular age-related macular degeneration. Expert Rev Ophthalmol. 2020;15(2):83–91. doi:10.1080/17469899.2020.1745062.
   Web of Science ®Google Scholar
• Casalino G, Bandello F, Chakravarthy U. Changes in neovascular lesion hyperreflectivity after anti-VEGF treatment in age-related macular degeneration: an integrated multimodal imaging analysis. Invest Ophthalmol Vis Sci. 2016;57:OCT288–98. doi:10.1167/iovs.15-18753.
   PubMed Web of Science ®Google Scholar
• Casalino G, Stevenson MR, Bandello F, Chakravarthy U. Tomographic biomarkers predicting progression to fibrosis in treated neovascular age-related macular degeneration: a multimodal imaging study. Ophthalmol Retina. 2018;2:451–61. doi:10.1016/j.oret.2017.08.019.
   PubMedGoogle Scholar
• Casalino G, Sivagnanavel V, Dowlut S, Keane PA, Chakravarthy U. Spontaneous retinal pigment epithelial tear in type 2 choroidal neovascularization: repair mechanisms following anti-VEGF therapy. Int J Retina Vitreous. 2019;5(1):4. doi:10.1186/s40942-019-0155-1.
   PubMedGoogle Scholar
• Wecker T, Grundel B, Reichl S, Stech M, Lange C, Agostini H, Böhringer D, Stahl A. Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment. Sci Rep. 2019;9(1):3301. doi:10.1038/s41598-019-38934-8.
   PubMed Web of Science ®Google Scholar
• Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Hykin P, Staurenghi G, Wittrup-Jensen K, Altemark A, Nilsson J, et al. Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol. 2016;100(12):1623–28. doi:10.1136/bjophthalmol-2015-308166.
   PubMed Web of Science ®Google Scholar
• Sadda SR, Guymer R, Monés JM, Tufail A, Jaffe GJ. Anti-vascular endothelial growth factor use and atrophy in neovascular age-related macular degeneration: systematic literature review and expert opinion. Ophthalmology. 2020;127:648–59. doi:10.1016/j.ophtha.2019.
   PubMed Web of Science ®Google Scholar
• CATT Research Group, Grunwald JE, Daniel E, Huang J, Ying G, MG M, CA T, GJ J, SL F, Blodi B, ML K, et al. Risk of geographic atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2014;121:150e161. doi:10.1016/j.ophtha.2013.08.015.
   Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC, IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382:1258e1267. doi:10.1016/S0140-6736(13)61501-9.
   Web of Science ®Google Scholar
• Grunwald JE, Pistilli M, Ying GS, Maguire MG, Daniel E, Martin DF. Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122(4):809–16. doi:10.1016/j.ophtha.2014.11.007.
   PubMed Web of Science ®Google Scholar
• Gune S, Abdelfattah NS, Karamat A, Balasubramanian S, Marion KM, Morgenthien E, Sadda SR. Spectral-domain OCT-based prevalence and progression of macular atrophy in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology. 2020;127(4):523–32. doi:10.1016/j.ophtha.2019.09.030.
   PubMed Web of Science ®Google Scholar
• Christakis PG, Agrón E, Klein ML, Clemons TE, Campbell JP, Ferris FL, Chew EY, Keenan TD. Age-related eye diseases study research group. incidence of macular atrophy after untreated neovascular age-related macular degeneration: age-related eye disease study report 40. Ophthalmology. 2020;127(6):784–92. doi:10.1016/j.ophtha.2019.11.016.
   PubMed Web of Science ®Google Scholar
• Long D, Kanan Y, Shen J, Hackett SF, Liu Y, Hafiz Z, Khan M, Lu L, Campochiaro PA. VEGF/VEGFR2 blockade does not cause retinal atrophy in AMD-relevant models. JCI Insight. 2018;3(10):e120231. doi:10.1172/jci.insight.120231.
   PubMed Web of Science ®Google Scholar
• Abdelfattah NS, Sadda J, Wang Z, Hu Z, Sadda S. Near-infrared reflectance imaging for quantification of atrophy associated with age-related macular degeneration. Am J Ophthalmol. 2020;212:169–74. doi:10.1016/j.ajo.2020.01.005.
   PubMed Web of Science ®Google Scholar
• Lindner M, Böker A, Mauschitz MM, Göbel AP, Fimmers R, Brinkmann CK, Schmitz-Valckenberg S, Schmid M, Holz FG, Fleckenstein M, Fundus Autofluorescence in Age-Related Macular Degeneration Study Group. Directional kinetics of geographic atrophy progression in age-related macular degeneration with foveal sparing. Ophthalmology. 2015;122(7):1356–65. doi:10.1016/j.ophtha.2015.03.027.
   PubMed Web of Science ®Google Scholar
• Monés J, Biarnés M. The rate of progression of geographic atrophy decreases with increasing baseline lesion size even after the square root transformation. Transl Vis Sci Technol. 2018;7(6):40. doi:10.1167/tvst.7.6.40.
   PubMed Web of Science ®Google Scholar